Valeant Pharmaceuticals International Inc.’s merger talks with Actavis Inc. have stalled because of a disagreement on price, according to people familiar with the matter.
Actavis Inc. agreed to sell assets covering four generic drugs in a settlement with U.S. regulators that clears the way for its $8.5 billion acquisition of Warner Chilcott Plc.
Bayer AG and a Merck KGaA unit sued Actavis Inc. in Delaware over a planned generic version of the birth-control drug Safyral.
Actavis Inc.’s generic version of the painkiller Fentora wouldn’t infringe two patents owned by Teva Pharmaceutical Industries Ltd.’s Cephalon unit, a U.S. appeals court ruled today.
Shire Plc agreed to a legal settlement preventing Actavis Inc. from introducing a low-cost copy of Shire’s Intuniv drug for attention-deficit hyperactivity disorder until December 2014.
UCB Inc. sued Actavis Inc., Novartis AG’s Sandoz unit and more than 13 other drugmakers alleging patent infringement for plans to sell low-cost generic versions of the epilepsy medicine Vimpat.
U.S. regulators, armed with a year- old Supreme Court decision, are stepping up probes of pharmaceutical deals that delay the sale of generic drugs, arrangements they view as illegally hurting competition.